JYNT · Joint Corp - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | $117.70M | $101.91M | $80.86M | $58.68M |
| Cost of Revenue | $11.23M | $11.52M | $10.55M | $9.83M | $8.51M | $6.51M |
| Gross Profit | - | - | $107.15M | $92.08M | $72.35M | $52.18M |
| R&D | - | - | - | - | - | - |
| SG&A | $44.58M | $42.12M | $106.59M | $89.59M | $66.97M | $46.73M |
| Total Operating Expenses | - | - | - | - | - | - |
| D&A | $1.71M | $4.72M | $8.58M | $7.64M | $6.09M | $2.73M |
| Operating Income | ($913.4K) | ($1.76M) | ($2.07M) | $2.08M | $5.35M | $5.49M |
| Interest Expense | - | - | - | - | - | - |
| Income Tax | $38.7K | $62.1K | $11.39M | $766.5K | ($1.29M) | ($7.75M) |
| Net Income | $2.91M | ($5.80M) | ($9.75M) | $1.18M | $6.58M | $13.17M |
| EPS - Basic | $0.19 | ($0.57) | ($0.66) | $0.08 | $0.46 | $0.94 |
| EPS - Diluted | $0.19 | ($0.56) | ($0.65) | $0.08 | $0.44 | $0.90 |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $23.60M | $25.05M | $18.15M | $9.75M | $19.53M | $20.55M |
| Accounts Receivable | $2.85M | $2.59M | $3.72M | $3.91M | $3.70M | $1.85M |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $1.59M | $1.75M | $1.63M | $2.97M | $1.71M | $1.56M |
| Current Assets | $52.09M | $72.19M | $44.34M | $17.61M | $26.89M | $25.13M |
| Total Assets | $60.97M | $80.42M | $87.15M | $91.94M | $85.45M | $65.73M |
| Current Liabilities | $32.82M | $49.35M | $33.57M | $23.12M | $21.44M | $18.69M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $45.89M | $62.48M | $62.38M | $59.54M | $55.88M | $44.98M |
| Stockholders' Equity | $15.05M | $17.92M | $24.75M | $32.37M | $29.54M | $20.75M |
| Retained Earnings | ($24.80M) | ($30.44M) | ($21.91M) | ($12.34M) | ($13.52M) | ($20.47M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $1.84M | $9.42M | $14.68M | $11.08M | $15.23M | $11.18M |
| Investing Cash Flow | $6.27M | ($631.5K) | ($6.19M) | ($20.78M) | ($14.14M) | ($4.60M) |
| Financing Cash Flow | ($9.81M) | ($2.00M) | $174.1K | $328.6K | ($2.00M) | $5.60M |
| CapEx | $1.50M | $1.19M | $5.00M | $5.90M | $6.99M | $3.16M |
| Free Cash Flow | $334.7K | $8.23M | $9.68M | $5.19M | $8.24M | $8.03M |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | 91.0% | 90.4% | 89.5% | 88.9% |
| Operating margin | - | - | -1.8% | 2.0% | 6.6% | 9.4% |
| EBITDA margin | - | - | 5.5% | 9.5% | 14.1% | 14.0% |
| Net margin | - | - | -8.3% | 1.2% | 8.1% | 22.4% |
| Free cash flow margin | - | - | 8.2% | 5.1% | 10.2% | 13.7% |
| FCF / Net income | 0.12 | -1.42 | -0.99 | 4.40 | 1.25 | 0.61 |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | - | - | 90.6% | 87.9% | 82.8% | 79.6% |
| Effective tax rate | 1.3% | - | 695.1% | 39.4% | -24.5% | -143.3% |
| Return on assets | 4.8% | -7.2% | -11.2% | 1.3% | 7.7% | 20.0% |
| Return on equity | 19.3% | -32.3% | -39.4% | 3.6% | 22.3% | 63.5% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 1.59 | 1.46 | 1.32 | 0.76 | 1.25 | 1.35 |
| Quick ratio | 1.59 | 1.46 | 1.32 | 0.76 | 1.25 | 1.35 |
| Cash ratio | 0.72 | 0.51 | 0.54 | 0.42 | 0.91 | 1.10 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - |
| Equity multiplier | 4.05 | 4.49 | 3.52 | 2.84 | 2.89 | 3.17 |
| Liabilities / Assets | 0.75 | 0.78 | 0.72 | 0.65 | 0.65 | 0.68 |
| Efficiency | ||||||
| Asset turnover | - | - | 1.35 | 1.11 | 0.95 | 0.89 |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | 12d | 14d | 17d | 12d |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | 52d | 55d | 56d | 110d | 73d | 88d |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | 45.9x | - | - | 174.8x | 149.3x | 29.2x |
| P / B | 8.8x | 9.0x | 5.8x | 6.4x | 33.2x | 18.5x |
| P / S | - | - | 1.2x | 2.0x | 12.1x | 6.5x |
| EV / EBITDA | 136.0x | 45.8x | 19.3x | 20.4x | 84.0x | 44.1x |
| Growth | ||||||
| Revenue growth (YoY) | - | - | 15.5% | 26.0% | 37.8% | 21.1% |
| Revenue CAGR (3y) | - | - | 26.1% | 28.1% | 36.5% | 32.6% |
| Revenue CAGR (5y) | - | - | 29.9% | 32.3% | 31.6% | 33.5% |
| Gross profit growth (YoY) | - | - | 16.4% | 27.3% | 38.7% | 21.7% |
| Operating income growth (YoY) | 48.0% | 15.3% | - | -61.2% | -2.5% | 60.8% |
| Net income growth (YoY) | - | 40.6% | - | -82.1% | -50.1% | 296.2% |
| EPS growth (YoY) | - | 13.8% | - | -81.8% | -51.1% | 291.3% |
| EPS CAGR (3y) | 33.4% | - | - | -29.7% | - | - |
| EPS CAGR (5y) | -26.7% | - | - | - | - | - |
| FCF growth (YoY) | -95.9% | -15.0% | 86.6% | -37.1% | 2.7% | 98.8% |
| FCF CAGR (5y) | -47.0% | 15.3% | 17.4% | - | - | - |
| Book value growth (YoY) | -16.0% | -27.6% | -23.6% | 9.6% | 42.4% | 262.8% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2023-12-31.
Business segments
$117.70M totalCorporate Clinics$70.72M · 60.1%
Franchise Operations$46.98M · 39.9%
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
5/9
Neutral
- ✓Net income positive
- ✓Operating cash flow positive
- ✓ROA improved YoY
- ✗Cash flow > net income
- -Long-term debt decreased
- ✓Current ratio improved
- ✓No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Patent Owners & Lessors
Comparing JOINT Corp against the 5 most active filers in the same SIC group.